CN108744322B - Treatment equipment for asthenozoospermia - Google Patents
Treatment equipment for asthenozoospermia Download PDFInfo
- Publication number
- CN108744322B CN108744322B CN201810743118.1A CN201810743118A CN108744322B CN 108744322 B CN108744322 B CN 108744322B CN 201810743118 A CN201810743118 A CN 201810743118A CN 108744322 B CN108744322 B CN 108744322B
- Authority
- CN
- China
- Prior art keywords
- treatment
- shock wave
- generating unit
- ultrasonic
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010067162 Asthenospermia Diseases 0.000 title claims abstract description 39
- 208000007799 Asthenozoospermia Diseases 0.000 title claims abstract description 33
- 230000035939 shock Effects 0.000 claims abstract description 102
- 239000000523 sample Substances 0.000 claims abstract description 73
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 71
- 230000033001 locomotion Effects 0.000 claims abstract description 15
- 238000002604 ultrasonography Methods 0.000 claims description 25
- 206010003883 azoospermia Diseases 0.000 claims description 19
- 208000008634 oligospermia Diseases 0.000 claims description 18
- 230000036616 oligospermia Effects 0.000 claims description 18
- 231100000528 oligospermia Toxicity 0.000 claims description 18
- 238000001514 detection method Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 238000003860 storage Methods 0.000 claims description 8
- 230000007246 mechanism Effects 0.000 claims description 7
- 238000010304 firing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 210000000582 semen Anatomy 0.000 abstract description 10
- 241000282414 Homo sapiens Species 0.000 abstract description 8
- 208000007466 Male Infertility Diseases 0.000 abstract description 6
- 230000004071 biological effect Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000000704 physical effect Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 19
- 238000010586 diagram Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000019100 sperm motility Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000003892 Kartagener syndrome Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 201000009266 primary ciliary dyskinesia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000005659 seminal clot liquefaction Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 201000004822 varicocele Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0078—Ultrasound therapy with multiple treatment transducers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
- Percussion Or Vibration Massage (AREA)
Abstract
The invention relates to a weak sperm disease treatment device, comprising: the ultrasonic wave generating unit (1), the shock wave generating unit (2) and the treatment probes (3, 3 '), wherein the ultrasonic wave generating unit (1) and the shock wave generating unit (2) are operatively coupled with the treatment probes (3, 3 '), and can selectively emit therapeutic ultrasonic waves and/or therapeutic shock waves to the treatment site of the asthenozoospermia through the treatment probes (3, 3 '). The invention adopts an in-vitro treatment mode that the treatment probe selectively transmits the ultrasonic waves for treatment and/or the shock waves for treatment to the treatment part of the asthenozoospermia of the human body, utilizes the beneficial biological effect and physical effect brought by the ultrasonic waves and the shock waves to improve the quantity of the sperm which move forward in the semen and the forward movement capacity of the sperm, and improves the whole vitality of the sperm, thereby achieving the effect of treating the male infertility caused by the asthenospermia, and having convenient use and obvious treatment effect.
Description
Technical Field
The invention relates to the field of medical equipment, in particular to weak sperm disease treatment equipment.
Background
The movement function or the movement capability of the sperms is directly related to reproduction of human beings, and only the sperms which normally do forward movement can ensure that the sperms reach the ampulla of the oviduct and are combined with the ovum to form fertilized eggs. The normal ex-vivo sperm, prior to semen liquefaction, is restricted in its movement and exhibits good movement ability once semen is liquefied. Fertilization is also not possible if the sperm cannot swim to the location of the ovum within an optimal time because of factors affecting sperm motility, particularly forward movement. Moreover, if the sperm is in the vagina for too long, the acidic environment within the vagina may shorten the sperm survival time.
According to domestic literature reports, male infertility caused by semen abnormality is 70% -80%, and semen abnormality comprises azoospermia, oligospermia, necrospermia, low sperm motility, non-liquefaction of semen and the like. Sperm may be graded as A, B, C, D four according to their motility. The A-level sperms are sperms which move forward quickly and move well, the B-level sperms are sperms which move forward slowly, the moving direction can be changed after the forward movement, the general sperms move actively, the C-level sperms are sperms which move in situ in a peristaltic or rotary mode, and the D-level sperms are sperms which do not move in situ and possibly are dead sperms. Asthenospermia (assospermia) refers to a condition in which less than 50% of the sperm (class a and B) move forward or less than 25% of the sperm move class a in a semen parameter, also known as hypomotility.
The causes of asthenozoospermia are numerous, including infections, semen dyscrasias, immune factors, endocrine factors, kartagener's syndrome, chromosomal abnormalities, varicoceles, and living factors. The treatment is generally Western medicine, chinese medicine or combination of Chinese and Western medicine. Western medicine treatment comprises general treatment, etiology treatment, hormone therapy, urokinase injection (uPA) and the like, and traditional Chinese medicine treatment mainly comprises traditional Chinese medicine treatment. The existing treatment methods have longer treatment period, more complex treatment process and limited treatment effect, and in addition, the drug treatment often has certain side effects.
Disclosure of Invention
The invention aims to provide a weak sperm disease treatment device which can effectively improve the whole activity of sperm so as to treat male infertility caused by weak sperm disease.
To achieve the above object, the present invention provides a weak sperm disease treatment apparatus comprising: the ultrasonic wave generating unit and the shock wave generating unit are operatively coupled with the treatment probe, and can selectively send therapeutic ultrasonic waves and/or therapeutic shock waves to the treatment site of the asthenozoospermia through the treatment probe.
Further, the therapeutic probe is a single therapeutic probe, and can emit therapeutic ultrasonic waves and therapeutic shock waves to the weak-sperm therapeutic part.
Further, the therapeutic probe comprises an ultrasonic shock wave generator which is respectively and operably coupled with the therapeutic probe, the ultrasonic wave generating unit and the shock wave generating unit, and can combine therapeutic ultrasonic waves and therapeutic shock waves into ultrasonic shock waves and send the ultrasonic shock waves to the treatment position of the asthenozoospermia through the therapeutic probe.
Further, the treatment probe is a single treatment probe, and can independently emit therapeutic ultrasonic waves or therapeutic shock waves, or the treatment probe comprises a plurality of independent treatment probes which are respectively coupled with the ultrasonic wave generation unit and the shock wave generation unit.
Further, the ultrasonic frequency range of the low-intensity pulse ultrasonic wave adopted by the ultrasonic generating unit is 1-2 MHz, and the sound intensity range is 0.05-3W/cm 2 。
Further, the ultrasonic frequency range adopted by the ultrasonic generating unit is 1.5-1.7 MHz.
Further, the shock wave frequency range adopted by the shock wave generating unit is 1-6 Hz, and the energy range is 0.01-0.7 mJ/mm 2 。
Further, the method further comprises the following steps: and a control unit which is connected with the ultrasonic wave generating unit and the shock wave generating unit in a signal way and can respectively adjust the parameters of the therapeutic ultrasonic wave output by the ultrasonic wave generating unit and/or the therapeutic shock wave output by the shock wave generating unit.
Further, the method further comprises the following steps: the detection unit is arranged at the end part of the treatment probe and is in signal connection with the control unit, so that the tissue state parameters of the treatment part of the asthenozoospermia can be detected and transmitted to the control unit, and the control unit can control the ultrasonic wave generation unit and/or the shock wave generation unit according to the detected result of the detection unit.
Further, the method further comprises the following steps: and the parameter storage unit is in signal connection with the control unit and is used for storing a plurality of tissue state parameters corresponding to the treatment positions of the asthenozoospermia, and the control unit can inquire the parameter storage unit according to the selection instruction of the treatment positions of the asthenospermia and control the ultrasonic wave generation unit and/or the shock wave generation unit according to the inquiry result.
Further, the method further comprises the following steps: the control unit is used for controlling the ultrasonic wave generation unit and/or the shock wave generation unit according to the adjustment instruction received by the control panel.
Further, the method further comprises the following steps: a probe adjustment mechanism is operatively coupled to the treatment probe and is capable of adjusting a movement position and an emission angle of the treatment probe.
Further, the probe adjusting mechanism comprises a mechanical arm, the treatment probe is mounted at the end part of the mechanical arm, the weak-sperm disease treatment equipment further comprises a control unit, the control unit is respectively connected with the mechanical arm and the treatment probe in a signal mode, the mechanical arm can be controlled according to the weak-sperm disease treatment part to drive the treatment probe to move to the corresponding position of the weak-sperm disease treatment part, and the angle of the treatment probe is adjusted.
Further, the ultrasonic wave generating unit further comprises a first adjusting lens which is connected with the control unit in a signal manner and used for adjusting the focusing type of the therapeutic ultrasonic wave output by the ultrasonic wave generating unit.
Further, the shock wave generating unit further comprises a second adjusting lens which is connected with the control unit in a signal manner and is used for adjusting the focusing type of the therapeutic shock wave output by the shock wave generating unit.
Further, the focusing type includes one of plane waves, scattered waves, focused waves, and semi-focused waves.
Based on the technical scheme, the invention adopts an in-vitro treatment mode that the treatment probe selectively transmits the treatment ultrasonic waves generated by the ultrasonic wave generating unit and/or the treatment shock waves generated by the shock wave generating unit to the treatment part of the asthenozoospermia of the human body, utilizes the beneficial biological effects and physical effects brought by the ultrasonic waves and the shock waves to improve the number of sperm moving forward in the semen and the forward movement capacity of the sperm, and improves the overall activity of the sperm, thereby achieving the effect of treating the male infertility caused by the asthenospermia, and has convenient use and obvious treatment effect.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this application, illustrate embodiments of the invention and together with the description serve to explain the invention and do not constitute a limitation on the invention. In the drawings:
fig. 1 is a schematic structural diagram of a first embodiment of the asthenozoospermia treatment apparatus of the present invention.
Fig. 2 is a schematic structural diagram of a second embodiment of the asthenozoospermia treatment apparatus of the present invention.
Fig. 3 is a schematic structural view of a third embodiment of the asthenozoospermia treatment apparatus according to the present invention.
Fig. 4 is a schematic structural view of a fourth embodiment of the asthenozoospermia treatment apparatus of the present invention.
Fig. 5 is a schematic structural diagram of a fifth embodiment of the oligospermia treatment device according to the present invention.
Fig. 6 is a schematic structural view of a sixth embodiment of the oligospermia treatment device according to the present invention.
Detailed Description
The technical scheme of the invention is further described in detail through the drawings and the embodiments.
Fig. 1 is a schematic structural diagram of a first embodiment of the asthenozoospermia treatment apparatus according to the present invention. In this embodiment, the oligospermia treatment apparatus includes: an ultrasonic wave generating unit 1, a shock wave generating unit 2 and treatment probes 3,3', wherein the ultrasonic wave generating unit 1 and the shock wave generating unit 2 are operatively coupled with the treatment probes 3,3', and can selectively send therapeutic ultrasonic waves and/or therapeutic shock waves to the treatment site of asthenozoospermia through the treatment probes 3,3 '.
The ultrasound generating unit 1 may comprise an ultrasound excitation source, which generates therapeutic ultrasound waves that may transmit acoustic energy to the target tissue to cause a corresponding biological effect. From a physical point of view, ultrasound is a form of mechanical energy with high frequency pressure waves (1-12 MHz), which are used to induce biochemical changes at the cellular and molecular level by micro-mechanical pressure of pressure waves acting on human tissue. Therefore, when therapeutic ultrasound is emitted to a treatment site for asthenozoospermia (for example, testis or epididymis of adult male) by the therapeutic probe 3, the number of sperm in forward movement and the forward movement ability of sperm in semen can be effectively improved.
The shock wave generating unit 2 may include a shock wave driver, and the generated therapeutic shock wave may pass the shock wave through the body fluid and tissue of the human body to reach the affected part, and when the shock wave enters the human body, the medium (such as fat, tendon, ligament, and other soft tissue, bone tissue, etc.) and the corresponding acoustic impedance contacted by the shock wave are different, and the interface positions of the tissues with different acoustic impedances generate different mechanical stresses, which are represented by different tensile stresses and compressive stresses generated on the tissues. Wherein, the tensile stress can induce the loosening among tissues to promote microcirculation, while the compressive stress can promote the elastic deformation of cells to increase the oxygen uptake of the cells. In addition, the negative band at the tail of the pulse of the shock wave can cause cavitation effect, namely when the pressure applied to the fluid dynamic field is lower than the saturated vapor pressure of the liquid, molecules in the liquid can enter cavitation reaction nuclei and expand into an observable size. Cavitation effect is favorable for dredging occluded fine blood vessels and loosening the adhesion of joint soft tissues. The number of sperm moving forward in semen and the forward movement capacity of sperm can be effectively improved by utilizing the therapeutic effect of therapeutic shock waves.
In addition to the implementation principle, there are also certain differences in the therapeutic actions and side effects of many properties of therapeutic ultrasound waves and therapeutic shock waves (e.g. energy concentration, penetration, thermal effects, etc.). In this embodiment, the ultrasonic wave generating unit 1 and the shock wave generating unit 2 are both operatively coupled to the therapeutic probes 3,3', and the therapeutic ultrasonic wave generating unit 1 alone or the shock wave generating unit 2 alone or the ultrasonic wave generating unit 1 and the shock wave generating unit 2 together can be selected to emit therapeutic ultrasonic waves and therapeutic shock waves to the treatment site of asthenozoospermia according to the therapeutic requirements and the characteristics of therapeutic waves when the therapeutic probe is used by a patient or a therapist. When the ultrasonic wave generation unit 1 and the shock wave generation unit 2 are used in combination, the therapeutic ultrasonic wave and the therapeutic shock wave may be simultaneously or sequentially rotated.
The ultrasonic wave generating unit 1 and the shock wave generating unit 2 may be at least partially disposed inside the equipment cabinet, and may employ an upper computer part (e.g., a computer, a micro industrial personal computer, and/or an intelligent terminal, etc.) as a control unit to realize a control function. Electrical components such as power supplies may also be included in the equipment cabinet.
In the present embodiment, the ultrasonic frequency range of the low-intensity pulsed ultrasonic wave employed by the ultrasonic wave generating unit 1 is preferably 1 to 2MHz, and more preferably 1.5 to 1.7MHz. Within the preferable and more preferable ranges, not only can the treatment requirements be satisfied, but also the side effects caused by the ultrasonic waves can be reduced. Correspondingly, the sound intensity is preferably in the range of 0.05 to 3W/cm 2 . For the shock wave generating unit 2, it is possible to employ other shock wave frequency ranges of preferably 1 to 6Hz, and energy ranges of preferably 0.01 to 0.7mJ/mm 2 . Within the preferred and more preferred ranges, not only can the therapeutic requirements be met, but also the side effects caused by the shock waves can be reduced.
In fig. 1, the treatment probe 3,3' comprises a plurality of independent treatment probes, coupled to the ultrasound generating unit 1 and said shock wave generating unit 2, respectively. And as shown in fig. 2, a schematic structural diagram of a second embodiment of the asthenozoospermia treatment apparatus of the present invention is shown. In contrast to the previous embodiment, the treatment probe 3 of the present embodiment is a single treatment probe, and can emit treatment ultrasonic waves or treatment shock waves individually as needed.
Considering that there are certain side effects of both ultrasound and shock wave therapy, for example, the thermal effects of ultrasound can cause local temperature rise in tissues, which in turn can lead to changes in the activity of some enzymes that are very temperature sensitive (e.g., matrix metalloproteinase-1 and collagenase, etc.), leading to enzyme denaturation. Both ultrasonic waves and therapeutic waves can generate cavitation effects, and when transient cavitation occurs, adverse changes of biological functions of organism tissues can be caused, for example, damage to cell integrity and the like is caused, and further damage to capillaries and the like is caused, so that bleeding, scars, even nerve damage and the like are caused. That is, when an ultrasonic wave or a shock wave exceeding a certain energy is used for treating the tissues of the human body, a great degree of side effects may be brought to the human body, and if the energy is low, the therapeutic effect may be limited. In order to further improve the therapeutic effect and to improve the effect of side effects, the therapeutic probe 3 in the form of a single therapeutic probe can emit therapeutic ultrasonic waves or therapeutic shock waves alone, and can also emit therapeutic ultrasonic waves and therapeutic shock waves combined to the site of treatment of asthenozoospermia. The ultrasonic shock wave is a combination wave formed by superposition and combination of therapeutic ultrasonic waves and therapeutic shock waves. Under the same energy condition, the ultrasonic shock wave is adopted for treatment, so that the energy of each of the ultrasonic wave for treatment and the shock wave for treatment can be reduced to reduce side effects, and the difference of the two treatment waves in treatment effect is fully utilized, thereby achieving better treatment effect on male infertility caused by asthenozoospermia.
Fig. 3 is a schematic structural diagram of a third embodiment of the asthenozoospermia treatment apparatus according to the present invention. Compared with the previous embodiment, the present embodiment further includes an ultrasonic shock wave generator 4. The ultrasonic shock wave generator 4 is operatively coupled to the treatment probe 3, the ultrasonic wave generation unit 1 and the shock wave generation unit 2, respectively, and is capable of combining the therapeutic ultrasonic wave and the therapeutic shock wave into an ultrasonic shock wave and emitting the ultrasonic shock wave to the treatment site of asthenozoospermia through the treatment probe 3. The ultrasonic shock wave generator 4 may be added to the first embodiment, and the ultrasonic shock wave may be emitted by using either one of the treatment probes 3 and 3' or a new treatment probe.
Fig. 4 is a schematic structural view of a fourth embodiment of the asthenozoospermia treatment apparatus according to the present invention. Compared to the second embodiment, the present embodiment further includes a control unit 5. The control unit 5 is connected to the ultrasonic wave generation unit 1 and the shock wave generation unit 2 in a signal manner, and can adjust parameters of the therapeutic ultrasonic wave output from the ultrasonic wave generation unit 1 and/or the therapeutic shock wave output from the shock wave generation unit 2. The parameters here may include the ultrasound frequency, intensity, etc. of the therapeutic ultrasound waves, as well as the frequency, energy level, etc. of the therapeutic shock waves.
In addition to the above parameters, parameters such as the focusing mode and the focusing depth of the ultrasonic wave and the shock wave can be adjusted as needed. Accordingly, in some embodiments, the ultrasound generating unit 1 further comprises a first adjusting lens, which is in signal connection with the control unit 5, for adjusting the type of therapeutic ultrasound outputted by the ultrasound generating unit 1. In other embodiments, the shock wave generating unit 2 further comprises a second adjusting lens, which is in signal connection with the control unit 5, for adjusting the type of therapeutic shock wave output by the shock wave generating unit 2. The focusing type of the therapeutic ultrasound wave and the therapeutic shock wave in the above-described embodiments may include one of a plane wave, a dispersion wave, a focused wave, and a semi-focused wave.
These types of waves are manifestations of the wave as it emanates and are distinguished primarily from the density of the wave. Wherein plane waves are all beams which are parallel and are not focused nor diverged; the scattered wave is that the wave beam is divergent, and the wave density is smaller than the plane wave; the beam of the focused wave is converged on a focus, so that the energy is more concentrated, and the wave density is higher; a semi-focused wave is a wave between a focused wave and a plane wave in terms of wave density, and relatively speaking, the wave density is also between the two, and is larger than the plane wave and smaller than the focused wave. The first adjusting lens and the second adjusting lens can adopt acoustic lenses to change the focusing degree of ultrasonic waves or shock waves, and change the energy concentration degree by changing different focusing types so as to obtain different treatment effects.
Referring to fig. 4, the detection unit 6 may be further included in some embodiments of the oligospermia treatment device. The detecting unit 6 is arranged at the end part of the treatment probe 3, is in signal connection with the control unit 5, and can detect the tissue state parameters of the treatment part of the asthenozoospermia and transmit the parameters to the control unit 5. The control unit 5 is capable of controlling the ultrasonic wave generation unit 1 and/or the shock wave generation unit 2 based on the result detected by the detection unit 6. Due to the difference of each individual to be treated, the tissue state parameter (such as tissue density, etc.) of the treatment site of the patient is detected by the detection unit 6, and the relevant parameters of the ultrasonic wave generation unit 1 and/or the shock wave generation unit 2 are controlled according to the tissue state parameter, so that the ultrasonic wave generation unit 1 and/or the shock wave generation unit 2 can achieve more targeted and more effective treatment effects. The control unit 5 and the detection unit 6 described above are also applicable to the third embodiment and the third embodiment, and will not be described again here.
The control unit 5 may also use a look-up table method in addition to the detection result of the detection unit 6. Referring to fig. 5, a schematic structural diagram of a fifth embodiment of the oligospermia treating apparatus according to the present invention is shown. In comparison with the previous embodiment, the present embodiment may be provided with the control unit 5 by adding the parameter storage unit 7 or replacing the detection unit 6 with the parameter storage unit 7 to provide the tissue state parameter of the treatment site. The parameter storage unit 7 is in signal connection with the control unit 5 and is used for storing a plurality of tissue state parameters corresponding to the asthenozoospermia treatment positions. The control unit 5 can query the parameter storage unit 7 according to the selection instruction of the asthenozoospermia treatment part, and control the ultrasonic wave generation unit 1 and/or the shock wave generation unit 2 according to the query result. After the therapeutic probe is set at the desired treatment site, the therapist or patient issues a selection instruction for selecting the site, and the control unit 5 can inquire about the corresponding tissue state parameter based on the selection instruction.
In the above embodiments, the parameter adjustment of the ultrasonic wave generating unit 1 and the shock wave generating unit 2 may be automatically adjusted by the control unit according to the tissue state parameter of the treatment site, or may be manually adjusted by the therapist or the patient according to the actual needs. Accordingly, a fixed or movable control panel in signal connection with the control unit 5 may also be included in some embodiments. The control panel can receive an externally input adjustment command (for example, an adjustment command sent by a person by pressing a button or a key, or operating a handle or a knob, etc.) and transmit the adjustment command to the control unit 5, and the control unit 5 can control the ultrasonic wave generating unit 1 and/or the shock wave generating unit 2 according to the adjustment command received by the control panel.
To facilitate positional adjustment of the treatment probe, a probe adjustment mechanism may also be included in some embodiments. The probe adjusting mechanism is operatively coupled with the treatment probe, and is capable of adjusting the movement position and the emission angle of the treatment probe so that the treatment probe can be more accurately and conveniently aligned with the treatment site, thereby obtaining better treatment effect.
Fig. 6 is a schematic structural view of a sixth embodiment of the oligospermia treatment device according to the present invention. In comparison with the previous embodiments, the probe adjusting mechanism of the present embodiment includes a mechanical arm 8, and the treatment probe 3 is mounted at an end of the mechanical arm 8. The weak-sperm disease treatment equipment further comprises a control unit 5, wherein the control unit 5 is respectively connected with the mechanical arm 8 and the treatment probe 3 in a signal manner, and can control the mechanical arm 8 according to the weak-sperm disease treatment part to drive the treatment probe 3 to move to the corresponding position of the weak-sperm disease treatment part, and the angle of the treatment probe 3 is adjusted. For example, when a therapist performs treatment of asthenozoospermia on a male infertility patient, the control unit 5 may be operated to move the mechanical arm 8 and aim the treatment probe 3 at the scrotum of the patient and adjust the probe angle so that the emitting end of the probe is aimed at the testis, and then adjust parameters of the therapeutic shock wave, therapeutic ultrasonic wave or ultrasonic shock wave according to the actual needs of the patient and perform the treatment.
Finally, it should be noted that the above-mentioned embodiments are only for illustrating the technical scheme of the present invention and are not limiting; while the invention has been described in detail with reference to the preferred embodiments, those skilled in the art will appreciate that: modifications may be made to the specific embodiments of the present invention or equivalents may be substituted for part of the technical features thereof; without departing from the spirit of the invention, it is intended to cover the scope of the invention as claimed.
Claims (12)
1. A device for treating asthenozoospermia, comprising: an ultrasound generating unit (1), a shock wave generating unit (2) and a treatment probe (3, 3 '), the treatment probe (3, 3') being a single treatment probe, the ultrasound generating unit (1) and the shock wave generating unit (2) being both operatively coupled to the treatment probe (3, 3 '), a treatment ultrasound, a treatment shock wave or a combination of a treatment ultrasound and a treatment shock wave being able to be selectively emitted by the treatment probe (3, 3') to a treatment site for asthenozoospermia; wherein the ultrasonic wave generating unit (1) adoptsThe ultrasonic frequency range of the used low-intensity pulse ultrasonic wave is 1-2 MHz, and the sound intensity range is 0.05-3W/cm 2 The method comprises the steps of carrying out a first treatment on the surface of the The shock wave frequency range adopted by the shock wave generating unit (2) is 1-6 Hz, and the energy range is 0.01-0.7 mJ/mm 2 。
2. The oligospermia treatment device according to claim 1, further comprising an ultrasonic shockwave generator (4) operatively coupled to the treatment probe (3, 3 '), the ultrasonic generating unit (1) and the shockwave generating unit (2), respectively, capable of combining therapeutic ultrasound waves and therapeutic shockwaves into ultrasonic shockwaves and emitting ultrasonic shockwaves to the oligospermia treatment site via the treatment probe (3, 3').
3. The oligospermia treatment device according to claim 1, wherein the ultrasound generating unit (1) employs an ultrasound frequency in the range of 1.5 to 1.7MHz.
4. The oligospermia treatment device of claim 1, further comprising: and a control unit (5) which is connected with the ultrasonic wave generation unit (1) and the shock wave generation unit (2) in a signal manner and can adjust parameters of the therapeutic ultrasonic wave output by the ultrasonic wave generation unit (1) and/or the therapeutic shock wave output by the shock wave generation unit (2) respectively.
5. The oligospermia treatment device of claim 4, further comprising: the detection unit (6) is arranged at the end part of the treatment probe (3, 3'), is connected with the control unit (5) in a signal manner, can detect the tissue state parameter of the treatment part of the asthenozoospermia, and transmits the tissue state parameter to the control unit (5), and the control unit (5) can control the ultrasonic wave generation unit (1) and/or the shock wave generation unit (2) according to the result detected by the detection unit (6).
6. The oligospermia treatment device of claim 4, further comprising: the parameter storage unit (7) is in signal connection with the control unit (5) and is used for storing a plurality of tissue state parameters corresponding to the treatment positions of the asthenozoospermia, and the control unit (5) can inquire the parameter storage unit (7) according to a selection instruction of the treatment positions of the asthenospermia and control the ultrasonic wave generation unit (1) and/or the shock wave generation unit (2) according to an inquiry result.
7. The oligospermia treatment device of claim 4, further comprising: the control unit (5) can control the ultrasonic wave generation unit (1) and/or the shock wave generation unit (2) according to the adjustment instruction received by the control panel.
8. The oligospermia treatment device of claim 1, further comprising: a probe adjustment mechanism operatively coupled to the treatment probe (3, 3 ') capable of adjusting the position of movement and the firing angle of the treatment probe (3, 3').
9. The device according to claim 8, wherein the probe adjusting mechanism comprises a mechanical arm (8), the treatment probe (3, 3 ') is mounted at the end of the mechanical arm (8), the device further comprises a control unit (5), the control unit (5) is respectively connected with the mechanical arm (8) and the treatment probe (3, 3') in a signal manner, and the mechanical arm (8) can be controlled according to the treatment position of the asthenozoospermia to drive the treatment probe (3, 3 ') to move to the corresponding position of the treatment position of the asthenospermia and perform the angle adjustment of the treatment probe (3, 3').
10. The oligospermia treatment apparatus according to claim 4, wherein the ultrasound generating unit (1) further comprises a first adjusting lens in signal connection with the control unit (5) for adjusting a focus type of the therapeutic ultrasound outputted by the ultrasound generating unit (1).
11. The oligospermia treatment device according to claim 4, wherein the shock wave generating unit (2) further comprises a second adjusting lens in signal connection with the control unit (5) for adjusting the type of focus of the therapeutic shock wave output by the shock wave generating unit (2).
12. The oligospermia treatment device of claim 10 or 11, wherein the type of focus comprises one of plane waves, dispersive waves, focused waves, and semi-focused waves.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810743118.1A CN108744322B (en) | 2018-07-09 | 2018-07-09 | Treatment equipment for asthenozoospermia |
| PCT/CN2019/095071 WO2020011125A1 (en) | 2018-07-09 | 2019-07-08 | Asthenozoospermia treatment device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810743118.1A CN108744322B (en) | 2018-07-09 | 2018-07-09 | Treatment equipment for asthenozoospermia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108744322A CN108744322A (en) | 2018-11-06 |
| CN108744322B true CN108744322B (en) | 2024-03-29 |
Family
ID=63972735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810743118.1A Active CN108744322B (en) | 2018-07-09 | 2018-07-09 | Treatment equipment for asthenozoospermia |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN108744322B (en) |
| WO (1) | WO2020011125A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108744322B (en) * | 2018-07-09 | 2024-03-29 | 北京万孛力医疗器械有限公司 | Treatment equipment for asthenozoospermia |
| CN110042055B (en) * | 2019-04-29 | 2022-05-13 | 新乡医学院 | Operating table for cell ultrasound |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2715855A1 (en) * | 1976-04-06 | 1977-10-27 | Univ Missouri | DEVICE FOR SUPPRESSING SPERM DEVELOPMENT IN MEN |
| DE3808783A1 (en) * | 1988-03-16 | 1989-10-05 | Dornier Medizintechnik | STONE CRUSHING BY COMBINED TREATMENT |
| US4976255A (en) * | 1988-08-17 | 1990-12-11 | Siemens Aktiengesellschaft | Apparatus for extracorporeal lithotripsy using shock waves and therapeutic ultrasound |
| SU1729507A1 (en) * | 1990-04-04 | 1992-04-30 | Новосибирский сельскохозяйственный институт | Method of spermatogenesis stimulation in hogs |
| CA2385624A1 (en) * | 1999-10-05 | 2001-04-12 | Omnisonics Medical Technologies, Inc. | Method and apparatus for ultrasonic medical treatment, in particular, for debulking the prostate |
| WO2006047082A2 (en) * | 2004-10-22 | 2006-05-04 | General Patent, Llc | Pressure pulse/shock wave therapy methods and an apparatus for conducting the therapeutic methods |
| KR20090117208A (en) * | 2008-05-09 | 2009-11-12 | 주식회사 에이치엔티메디칼 | Shock wave and ultrasound wave integrated therapy device |
| EP3278839A1 (en) * | 2016-08-05 | 2018-02-07 | Axiosonic, LLC | Systems using ultrasound for treatment |
| CN107929019A (en) * | 2017-11-30 | 2018-04-20 | 广东美的安川服务机器人有限公司 | Shock wave treatment instrument and its control method |
| CN213220602U (en) * | 2018-07-09 | 2021-05-18 | 北京万孛力医疗器械有限公司 | Equipment for treating asthenospermia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10102317A1 (en) * | 2001-01-19 | 2002-08-14 | Hmt Ag | Method and device for applying pressure waves to the body of a living being |
| US7601127B2 (en) * | 2004-10-22 | 2009-10-13 | General Patent, Llc | Therapeutic stimulation of genital tissue or reproductive organ of an infertility or impotence diagnosed patient |
| US20140330174A1 (en) * | 2013-05-01 | 2014-11-06 | General Patent Llc | Method of acoustic shock wave treatments for complications associated with surgical mesh implants |
| WO2015106118A1 (en) * | 2014-01-09 | 2015-07-16 | Sonitec Llc | Systems and methods using ultrasound for treatment |
| CN105726190B (en) * | 2014-12-12 | 2019-10-29 | 北京东方百奥医药开发有限公司 | A kind of impulse ultrasound therapeutic equipment for male erectile dysfunction |
| CN108720897B (en) * | 2018-07-09 | 2023-12-05 | 北京万孛力医疗器械有限公司 | Combination wave therapy device and therapy system |
| CN108744322B (en) * | 2018-07-09 | 2024-03-29 | 北京万孛力医疗器械有限公司 | Treatment equipment for asthenozoospermia |
-
2018
- 2018-07-09 CN CN201810743118.1A patent/CN108744322B/en active Active
-
2019
- 2019-07-08 WO PCT/CN2019/095071 patent/WO2020011125A1/en active Application Filing
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2715855A1 (en) * | 1976-04-06 | 1977-10-27 | Univ Missouri | DEVICE FOR SUPPRESSING SPERM DEVELOPMENT IN MEN |
| DE3808783A1 (en) * | 1988-03-16 | 1989-10-05 | Dornier Medizintechnik | STONE CRUSHING BY COMBINED TREATMENT |
| US4976255A (en) * | 1988-08-17 | 1990-12-11 | Siemens Aktiengesellschaft | Apparatus for extracorporeal lithotripsy using shock waves and therapeutic ultrasound |
| SU1729507A1 (en) * | 1990-04-04 | 1992-04-30 | Новосибирский сельскохозяйственный институт | Method of spermatogenesis stimulation in hogs |
| CA2385624A1 (en) * | 1999-10-05 | 2001-04-12 | Omnisonics Medical Technologies, Inc. | Method and apparatus for ultrasonic medical treatment, in particular, for debulking the prostate |
| WO2006047082A2 (en) * | 2004-10-22 | 2006-05-04 | General Patent, Llc | Pressure pulse/shock wave therapy methods and an apparatus for conducting the therapeutic methods |
| KR20090117208A (en) * | 2008-05-09 | 2009-11-12 | 주식회사 에이치엔티메디칼 | Shock wave and ultrasound wave integrated therapy device |
| EP3278839A1 (en) * | 2016-08-05 | 2018-02-07 | Axiosonic, LLC | Systems using ultrasound for treatment |
| CN107929019A (en) * | 2017-11-30 | 2018-04-20 | 广东美的安川服务机器人有限公司 | Shock wave treatment instrument and its control method |
| CN213220602U (en) * | 2018-07-09 | 2021-05-18 | 北京万孛力医疗器械有限公司 | Equipment for treating asthenospermia |
Non-Patent Citations (3)
| Title |
|---|
| 体外冲击波与针刺治疗阳痿效果观察;吴天宇;王敏;当代临床医刊;20150430;第1525卷(第4期);全文 * |
| 物理因子抗生育作用的生物物理基础;吕昌祥, 龚尔璋;生殖与避孕;19840830(第04期);全文 * |
| 青年男性输尿管下段结石行体外冲击波碎石治疗对其精液的影响分析;钟小明;程支利;陈智彬;;中国性科学(第01期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108744322A (en) | 2018-11-06 |
| WO2020011125A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7507213B2 (en) | Pressure pulse/shock wave therapy methods for organs | |
| US7610079B2 (en) | Shock wave imaging system | |
| US8257282B2 (en) | Pressure pulse/shock wave apparatus for generating waves having plane, nearly plane, convergent off target or divergent characteristics | |
| US8512250B2 (en) | Component ultrasound transducer | |
| Bailey et al. | Physical mechanisms of the therapeutic effect of ultrasound (a review) | |
| EP1711109B1 (en) | Localized production of microbubbles and control of cavitational and heating effects by use of enhanced ultrasound | |
| US7883482B2 (en) | Pressure pulse/shock wave therapy methods and an apparatus for conducting the therapeutic methods | |
| US7601127B2 (en) | Therapeutic stimulation of genital tissue or reproductive organ of an infertility or impotence diagnosed patient | |
| ES2960905T3 (en) | Ultrasonic surgical instrument and related manufacturing procedure | |
| US20080058682A1 (en) | Device for ultrasound monitored tissue treatment | |
| JP4938024B2 (en) | Transducer cuff for high-intensity focused ultrasound guidance and application to control bleeding due to amputated limbs | |
| US20070142753A1 (en) | Pancreas regeneration treatment for diabetics using extracorporeal acoustic shock waves | |
| CN108744322B (en) | Treatment equipment for asthenozoospermia | |
| CN102210910A (en) | Ultrasonic transducer | |
| CN108720897B (en) | Combination wave therapy device and therapy system | |
| JP2002537013A (en) | Method and apparatus for uniform transdermal therapeutic ultrasound | |
| CN201675962U (en) | Gynaecology diagnosis and treatment integrated system | |
| WO2018018725A1 (en) | Two-stage hundred-microsecond pulse focused ultrasound tissue destruction method | |
| CN108187183B (en) | Built-in medical ultrasonic thrombolysis therapeutic apparatus | |
| CN213220602U (en) | Equipment for treating asthenospermia | |
| CN111420289B (en) | Head and device for treating chronic pelvic pain syndrome | |
| US20230372742A1 (en) | Acoustic shock wave treatment for erectile dysfunction | |
| TWI337087B (en) | ||
| CN204863371U (en) | Shock wave scattered signal's water tank device is measured with annular hydrophone array | |
| Kavya et al. | Application of Aerodynamic Shock Wave in Medical Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |